BioCentury | Apr 5, 2019
Tools & Techniques

Second shot for shRNA

...AML) the shRNA-modified product, CYAD-02, showed greater CAR T cell expansion and tumor killing than CYAD-01...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...Killer cell lectin-like receptor subfamily K member 1 (NKG2D; KLRK1; CD314) Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) CYAD-01...
BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

...Modality Target Status Activating receptors Celyad S.A. (NASDAQ:CYAD; Euronext:CYAD) / Ono Pharmaceutical Co. Ltd. (Tokyo:4528) CYAD-01...
BioCentury | May 17, 2018
Emerging Company Profile

Beyond B cells

...testing against non-B cell targets for AML, according to BioCentury’s BCIQ database. Celyad S.A. has CYAD-01...
...K member 1 Jennie Walters, Staff Writer CAR T cell therapy targeting CD33 CAR-T NKR-2 (CM-CS1, CYAD-01, NKR-2, car-nkg2d, nkg2d car t cells) Celyad...
BioCentury | Nov 6, 2017
Preclinical News

Team identifies new target for MM CAR T therapy

...Tokyo:4528) and Institut Curie (Paris, France) to develop autologous CAR T cells using NKG2D (CAR-T NKR-2). CAR-T NKR-2...
BioCentury | Oct 6, 2017
Clinical News

Celyad’s CAR T leads to leukemia-free state in AML patient

...state (MLFS) after receiving the company's chimeric antigen receptor (CAR) T cell therapy (CAR-T NKG2D, CAR-T NKR-2...
...a gene-engineered T cell therapy without prior pre-conditioning chemotherapy. The AML patient received 3x10 8 CYAD-01...
...Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD), Mont-Saint-Guibert, Belgium Dartmouth College , Hanover, N.H. Product: CYAD-01 (CAR-T NKG2D, CAR-T NKR-2...
BioCentury | Aug 10, 2017
Company News

Celyad amends CAR T deal

...a more front-loaded deal after initial data from the Phase I THINK trial of CAR-T NKR-2 (CYAD-01...
...solid and hematological tumors led to "increased confidence in the clinical opportunity" of the candidate. CAR-T NKR-2...
...Celyad purchased Celdara's Oncyte oncology division and its portfolio of CAR T cell products, including CAR-T NKR-2...
BioCentury | Aug 4, 2017
Company News

Celyad gains on CAR T deal amendment

...a more front-loaded deal after initial data from the Phase I THINK trial of CAR-T NKR-2 (CYAD-01...
...solid and hematological tumors led to "increased confidence in the clinical opportunity" of the candidate. CAR-T NKR-2...
...Celyad purchased Celdara's Oncyte oncology division and its portfolio of CAR T cell products, including CAR-T NKR-2...
BioCentury | Jun 29, 2017
Product R&D

Drop the MIC

...Pharmaceutical Co. Ltd. and Institut Curie to develop autologous CAR T cells using NKG2D, dubbed CAR-T NKR-2...
...of the immune system and toxicity.” But according David Gilham, VP of R&D at Celyad, CAR-T NKR-2...
BioCentury | Jun 14, 2017
Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting endosomal TACR1 signaling could help treat chronic pain. In mouse models of capsaicin-induced allodynia, formalin-induced pain and complete Freund's adjuvant (CFA)-induced hyperalgesia, peptide inhibitors of TACR1 endocytosis decreased pain...
Items per page:
1 - 10 of 19